Treatments for SMA are available, but unaffordable for most Malaysians

WeCareJourney co-founder and Lim's wife Yap Sook Yee prepares the daily dose of risdiplam for their son Branden. This drug, which is based on patient weight, is estimated to cost a maximum of US$340,000 (RM1.5mil) a year.

In the past six years or so, patients with spinal muscular atrophy (SMA) and their families were filled with hope as treatments for this rare disease were confirmed to be effective and approved by regulatory agencies around the world.

Previously without treatment and with a limited lifespan for the majority of patients, this progressive disease now has three available drugs that tackle the condition directly.

Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Next In Health

Breast implants help save man in need of lung transplant
Outwardly fine, but internally anxious
Up your fitness levels by walking on an incline
Presence of deep fat linked to Alzheimer’s disease risk
Thalassaemia: From mild anaemia to death at birth
Premature babies: Hold off on clamping the umbilical cord
How to reverse pre-diabetes before it becomes diabetes
Got gout? Avoid these foods to reduce your uric acid
A tax on sugar could help control our sweet tooth
When loneliness leads to premature death

Others Also Read